GLPwatch
C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Diabetes Res Clin Pract · 2012
Last updated 2026-05-28In a study of people taking liraglutide, an improvement in blood sugar control was linked to better early insulin response during a glucose test. The body's C-peptide response to a glucagon challenge was strongly connected to this improvement, suggesting it could help predict how well liraglutide will work.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2012 |
|---|---|
| Citations | 19 |
| Relative citation ratio | 0.63 |
| NIH percentile | 35 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
The amelioration of glucose tolerance by liraglutide was associated with a significant improvement of early insulin-response during OGTT. The serum C-peptide response to glucagon challenge strongly correlated with the improvement of the early insulin-response. The C-peptide response to glucagon challenge would be useful to predict therapeutic response to liraglutide.
Verbatim abstract via PubMed 23068961 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.